Back to Journals » Clinical Ophthalmology » Volume 3

Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden

Authors Bergström A, Maurel F, Pen CL, Lamure E, Kent M, Bardoulat I, Berdeaux G

Published 16 August 2009 Volume 2009:3 Pages 471—481

DOI https://doi.org/10.2147/OPTH.S6811

Review by Single-blind

Peer reviewer comments 3


Anders Bergström1, Frédérique Maurel2, Claude Le Pen3, Emilie Lamure2, Michael Kent4, Isabelle Bardoulat2, Gilles Berdeaux5,6

1Lund Hospital, Lund, Sweden; 2IMS France, Puteaux, France; 3Université Paris-Dauphine, Paris, France; 4Alcon Inc, Fort Worth, Texas, USA; 5Alcon France SA, Rueil-Malmaison, France; 6Conservatoire National des Arts et Métiers, Paris, France

Background: To compare the daily costs of 3 prostaglandin analogues (bimatoprost, latanoprost, travoprost), alone, and associated with timolol in 4 European countries (Denmark, Finland, Germany, and Sweden).

Methods: Six glaucoma products were sampled by buying 5 bottles from 1 suburban pharmacy in each of the 4 countries. Drops were weighed by a single operator at 1 site according to standardized procedures. Residual drops were then counted. Unit bottle costs were estimated from tariff lists. Eye-drop weights were entered into a nested analysis of variance comprising drug, instillation day, country, the interaction, and a sample factor nested within the country factor. Effectiveness was represented by treatment failure rates estimated from a meta-analysis and a general practitioner survey.

Results: Every drug bottle contained sufficient drops to treat 1 patient for 28/31 days. Drop-size heterogeneity between countries was observed for bimatoprost and bimatoprost/timolol. Mean travoprost and travoprost/timolol drop-sizes were the smallest, and drop-counts per bottle were the lowest for latanoprost, or latanoprost/timolol. In all 4 countries annual costs were least for travoprost and travoprost/timolol.

Conclusions: On taking into account drug costs and effectiveness, travoprost and travoprost/timolol were cheaper and more effective than latanoprost and latanoprost/timolol and were cheaper than bimatoprost and bimatoprost/timolol.

Keywords: prostaglandin analogue, economics, daily cost

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]